Skip to main content

Articles

Page 2 of 39

  1. The influence of duration of type 2 diabetes mellitus (T2DM) on the likelihood of developing new-onset dementia in post-stroke population is not well understood. Therefore, we aimed to clarify the relationship...

    Authors: Jonguk Kim, Kyung-Do Han, Jeong-Yoon Lee, Ye Seul Yang, Dae Young Cheon, Jae-Jun Lee and Minwoo Lee
    Citation: Alzheimer's Research & Therapy 2025 17:58
  2. Rare variants of the triggering receptor expressed on myeloid cell 2 (TREM2) gene are strong risk factors for Alzheimer’s disease (AD), and drugs targeting the TREM2 protein are being developed. However, it is un...

    Authors: Janna I. R. Dijkstra, Lisa Vermunt, Vikram Venkatraghavan, Georgii Ozhegov, Emma M. Coomans, Rik Ossenkoppele, Elsmarieke van de Giessen, Marc Hulsman, Christa M. de Geus, Wiesje M. van der Flier, Sietske A. M. Sikkes, Frederik Barkhof, Betty Tijms, Alida A. Gouw, Willem de Haan, Everard G. B. Vijverberg…
    Citation: Alzheimer's Research & Therapy 2025 17:57
  3. We investigated how cerebrospinal fluid levels of synaptic proteins associate with memory function in normal cognition (CN) and mild cognitive impairment (MCI), and investigated the effect of amyloid positivit...

    Authors: Kirsten E. J. Wesenhagen, Diederick M. de Leeuw, Jori Tomassen, Johan Gobom, Isabelle Bos, Stephanie J. B. Vos, Pablo Martinez-Lage, Mikel Tainta, Julius Popp, Gwendoline Peyratout, Magda Tsolaki, Rik Vandenberghe, Yvonne Freund-Levi, Frans Verhey, Simon Lovestone, Johannes Streffer…
    Citation: Alzheimer's Research & Therapy 2025 17:56
  4. Abnormal excitability of hippocampal neurons may lead to dysfunction of neural circuits and then causes cognitive impairments in Alzheimer’s disease (AD). However, the underlying mechanisms remain to be fully ...

    Authors: Xiaoqin Zhang, Yiping Zhang, Ting Zhang, Jing Wang, Chang Liu, Qing Shang, Xiaojie Wei, Huaqiang Zhu, Haowei Shen and Binggui Sun
    Citation: Alzheimer's Research & Therapy 2025 17:55
  5. Variants in PSEN1, PSEN2, and APP are major genetic causes of early-onset Alzheimer’s disease (EOAD). Our study aimed to identify the genotypic and phenotypic spectrums in a Chinese EOAD cohort and confirm their ...

    Authors: Haitian Nan, Min Chu, Deming Jiang, Wenping Liang, Yu Li, Yiming Wu, Zhe Wang and Liyong Wu
    Citation: Alzheimer's Research & Therapy 2025 17:54
  6. Alzheimer’s disease (AD) is the leading cause of dementia, and the early detection of the disease-associated changes allows early interventions. The locus coeruleus (LC) has been reported to be the first brain...

    Authors: Junjie Wu, Aaron Toporek, Qixiang Lin, Felicia C. Goldstein, David W. Loring, Michael A. Kelberman, David Weinshenker, Allan I. Levey, James J. Lah and Deqiang Qiu
    Citation: Alzheimer's Research & Therapy 2025 17:53
  7. Recent studies have focused on improving our understanding of gut microbiome dysbiosis and its impact on cognitive function. However, the relationship between gut microbiome composition, accelerated brain atro...

    Authors: Sang Joon Son, Dong Yun Lee, Hyun Woong Roh, Maria Ly, Antonija Kolobaric, Howard Aizenstein, Carmen Andreescu, Eldin Jašarević, Tharick A. Pascoal, Pamela C. L Ferreira, Bruna Bellaver, Yong Hyuk Cho, Sunhwa Hong, You Jin Nam, Bumhee Park, Narae Kim…
    Citation: Alzheimer's Research & Therapy 2025 17:52
  8. Synaptic protein levels in cerebrospinal fluid (CSF) may represent much-needed objective biomarkers of cognitive impairment, disease progression and drug efficacy in patients with dementia with Lewy bodies (DL...

    Authors: Alba Cervantes González, Julie Goossens, Elena Vera Campuzano, Isabel Sala, M. Belén Sánchez-Saudinós, Íñigo Rodríguez-Baz, Laia Lidón, Danna Perlaza, Alexandre Bejanin, Annakaisa Haapasalo, Juan Fortea, Daniel Alcolea, Alberto Lleó, Eugeen Vanmechelen and Olivia Belbin
    Citation: Alzheimer's Research & Therapy 2025 17:51
  9. Social frailty, a multidimensional construct encompassing various social behaviors, resources, and needs, significantly impacts cognitive health in older adults. Despite existing studies linking specific socia...

    Authors: Hui Zhang, Meng Hao, Zixin Hu, Shuai Jiang, Yi Li, Xiaofeng Wang and Xiangwei Li
    Citation: Alzheimer's Research & Therapy 2025 17:50
  10. Amyloid-β peptide (Aβ) species of 42 or 43 amino acids in length (Aβ42/43) trigger Alzheimer´s disease (AD) and are produced in abnormal amounts by mutants of the γ-secretase subunit presenilin-1 (PS1), which ...

    Authors: Johannes Trambauer, Rosa Maria Rodriguez Sarmiento, Holly J. Garringer, Katja Salbaum, Liliana D. Pedro, Dennis Crusius, Ruben Vidal, Bernardino Ghetti, Dominik Paquet, Karlheinz Baumann, Lothar Lindemann and Harald Steiner
    Citation: Alzheimer's Research & Therapy 2025 17:49

    The Correction to this article has been published in Alzheimer's Research & Therapy 2025 17:83

  11. Impaired kidney function has a potential confounding effect on blood biomarker levels, including biomarkers for Alzheimer’s disease (AD). Given the imminent use of certain blood biomarkers in the routine diagn...

    Authors: Burak Arslan, Wagner S. Brum, Ilaria Pola, Joseph Therriault, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Kübra Tan, Paolo Vitali, Maxime Montembeault, Jesse Klostranec, Arthur C. Macedo, Cecile Tissot, Serge Gauthier, Juan Lantero-Rodriguez, Eduardo R. Zimmer…
    Citation: Alzheimer's Research & Therapy 2025 17:48
  12. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in which mitochondrial dysfunction and neuroinflammation play crucial roles in its progression. Our previous studies found that cornuside from

    Authors: Fulin Zhou, Wenwen Lian, Xiaotang Yuan, Zexing Wang, Congyuan Xia, Yu Yan, Wenping Wang, Zhuohang Tong, Yungchi Cheng, Jiekun Xu, Jun He and Weiku Zhang
    Citation: Alzheimer's Research & Therapy 2025 17:47

    The Correction to this article has been published in Alzheimer's Research & Therapy 2025 17:63

  13. This study investigated sex differences in the associations between Alzheimer’s disease (AD) biomarkers, cognitive performance, and decline in memory clinic settings.

    Authors: Cecilia Boccalini, Debora Elisa Peretti, Max Scheffler, Linjing Mu, Alessandra Griffa, Nathalie Testart, Gilles Allali, John O. Prior, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Giovanni B. Frisoni and Valentina Garibotto
    Citation: Alzheimer's Research & Therapy 2025 17:46
  14. Autosomal dominant Alzheimer’s disease (ADAD) offers a distinct framework to study the preclinical phase of Alzheimer’s disease (AD), due to its predictable symptom onset and high penetrance of causative mutat...

    Authors: Zhi Zhou, Qigeng Wang, Linwen Liu, Qi Wang, Xiaojun Zhang, Can Li, Jiajin Liu, Yidan Wei, Jin Gao, Liping Fu and Ruimin Wang
    Citation: Alzheimer's Research & Therapy 2025 17:45

    The Correction to this article has been published in Alzheimer's Research & Therapy 2025 17:87

  15. Abnormal microglial polarization phenotypes contribute to the pathogenesis of Alzheimer’s disease (AD). Circular RNAs (circRNAs) have garnered increasing attention due to their significant roles in human disea...

    Authors: Deng-Pan Wu, Yan-Su Wei, Li-Xiang Hou, Yu-Xuan Du, Qiu-Qing Yan, Ling-Ling Liu, Yuan-Dan Zhao, Ru-Yu Yan, Chao Yu, Zhen-Guo Zhong and Jin-Lan Huang
    Citation: Alzheimer's Research & Therapy 2025 17:44
  16. Blood-based assays are expected to be integrated into clinical routines across various contexts, including Alzheimer’s disease (AD). Vascular dementia (VaD), which is the second most common cause leading to de...

    Authors: Constance Delaby, Daniel Alcolea, Germain Busto, Audrey Gabelle, Xavier Ayrignac, Karim Bennys, Elena Muiño, Paula Villatoro, Israel Fernández-Cadenas, Nicolas Pradeilles, Shaima El Bounasri, Soraya Torres, Christophe Hirtz, Henrik Zetterberg, Alberto Lleó, Juan Fortea…
    Citation: Alzheimer's Research & Therapy 2025 17:42
  17. Early diagnosis and accurate prognosis of cognitive decline in Alzheimer’s disease (AD) is important to timely assignment to optimal treatment modes. We aimed to develop a deep learning model to predict cognit...

    Authors: Siyu Yang, Xintong Zhang, Xinyu Du, Peng Yan, Jing Zhang, Wei Wang, Jing Wang, Lei Zhang, Huaiqing Sun, Yin Liu, Xinran Xu, Yaxuan Di, Jin Zhong, Caiyun Wu, Jan D. Reinhardt, Yu Zheng…
    Citation: Alzheimer's Research & Therapy 2025 17:41
  18. The importance of natural killer (NK) cells of the innate immune system in neurodegenerative disease has largely been overlooked despite studies demonstrating their ability to reduce neuroinflammation (thought...

    Authors: Clemente Humberto Zúñiga, Blanca Isaura Acosta, Rufino Menchaca, Cesar A. Amescua, Sean Hong, Lucia Hui, Minchan Gil, Yong-hee Rhee, Sangwook Yoon, Minji Kim, Paul Y. Chang, Yong Man Kim, Paul Y. Song and Katia Betito
    Citation: Alzheimer's Research & Therapy 2025 17:40
  19. β-synuclein (β-syn), mainly expressed in central nerve system, is one of the biomarkers in cerebrospinal fluid (CSF) and blood for synaptic damage, which has been reported to be elevated in CSF and blood of th...

    Authors: Bing Xu, Kang Xiao, Xiaoxi Jia, Rundong Cao, Donglin Liang, Ruhan A, Weiwei Zhang, Chunjie Li, Liping Gao, Cao Chen, Qi Shi and Xiaoping Dong
    Citation: Alzheimer's Research & Therapy 2025 17:39
  20. The clinical presentations of early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease are distinct, with EOAD having a more aggressive disease course with greater heterogeneity. Recent public...

    Authors: Deepti Putcha, Yuta Katsumi, Alexandra Touroutoglou, Ani Eloyan, Alexander Taurone, Maryanne Thangarajah, Paul Aisen, Jeffrey L. Dage, Tatiana Foroud, Clifford R. Jack Jr., Joel H. Kramer, Kelly N. H. Nudelman, Rema Raman, Prashanthi Vemuri, Alireza Atri, Gregory S. Day…
    Citation: Alzheimer's Research & Therapy 2025 17:38
  21. Numerous studies have demonstrated the effects of transcranial direct current stimulation (tDCS) on cognitive function in the older people. This study further explores the impact of tDCS and its dosage paramet...

    Authors: Thatchaya Prathum, Thanwarat Chantanachai, Oranich Vimolratana, Chotica Laksanaphuk, Irin Apiworajirawit, Benchaporn Aneksan, Kanthika Latthirun, Cheng-Ta Yang and Wanalee Klomjai
    Citation: Alzheimer's Research & Therapy 2025 17:37
  22. Gut microbiota dysbiosis is linked to Alzheimer’s disease (AD), but our understanding of the molecular and neuropathological bases underlying such association remains fragmentary.

    Authors: Han Zhao, Xia Zhou, Yu Song, Wenming Zhao, Zhongwu Sun, Jiajia Zhu and Yongqiang Yu
    Citation: Alzheimer's Research & Therapy 2025 17:36
  23. Recent studies suggest that opioid receptor signaling may differentially affect Alzheimer’s disease (AD) pathology and the relevant behavioral dysfunctions. However, the precise roles and mechanisms of opioid ...

    Authors: Yuan Xu, Naiyuan Shao, Feng Zhi, Ronghua Chen, Yilin Yang, Jiahui Li, Ying Xia and Ya Peng
    Citation: Alzheimer's Research & Therapy 2025 17:35
  24. Early Alzheimer’s disease diagnosis is crucial for preventive therapy development. Standard neuropsychological evaluation does not identify clinically normal individuals with brain amyloidosis, the first stage...

    Authors: Lise Colmant, Lisa Quenon, Lara Huyghe, Adrian Ivanoiu, Thomas Gérard, Renaud Lhommel, Pauline Coppens, Yasmine Salman, Vincent Malotaux, Laurence Dricot, Lukas Kunz, Nikolai Axmacher, Philippe Lefèvre and Bernard Hanseeuw
    Citation: Alzheimer's Research & Therapy 2025 17:34
  25. The nature and severity of Alzheimer’s disease (AD) pathologies in the retina and brain correspond. However, retinal biomarkers need to be validated in clinical cohorts with confirmed AD biomarkers and optical...

    Authors: Zi Jin, Xinmin Wang, Ying Lang, Yufeng Song, Huangxiong Zhan, Wuge Shama, Yingying Shen, Guihua Zeng, Faying Zhou, Hongjian Gao, Shuling Ye, Yanjiang Wang, Fan Lu and Meixiao Shen
    Citation: Alzheimer's Research & Therapy 2025 17:33
  26. We consider the recent publication by Ornish and colleagues and the rigor expected for interventional clinical trials. We contend that lifestyle intervention trials should strive for the same rigor as drug tri...

    Authors: Joshua D. Grill and Daniel Gillen
    Citation: Alzheimer's Research & Therapy 2025 17:32
  27. The emerging evidence of the role of the glymphatic system (GS) in Alzheimer’s disease (AD) provides new opportunities for intervention from the earliest stages of the disease. The aim of the study is to evalu...

    Authors: Natalia Cullell, Giovanni Caruana, Andrea Elias-Mas, Ariane Delgado-Sanchez, Cristina Artero, Maria Teresa Buongiorno, Marta Almería, Nicola J. Ray, Sonia A. L. Correa and Jerzy Krupinski
    Citation: Alzheimer's Research & Therapy 2025 17:31
  28. Specific genetic variants in the ATP-binding cassette transporter A7 locus (ABCA7) are associated with an increased risk of Alzheimer’s disease (AD). ABCA7 transports lipids from/across cell membranes, regulates ...

    Authors: Irene Santos-García, Pablo Bascuñana, Mirjam Brackhan, María Villa, Ivan Eiriz, Thomas Brüning and Jens Pahnke
    Citation: Alzheimer's Research & Therapy 2025 17:30
  29. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting millions worldwide, leading to cognitive and functional decline. Early detection and intervention are crucial for enhancing the qu...

    Authors: Manuel Lentzen, Srinivasan Vairavan, Marijn Muurling, Vasilis Alepopoulos, Alankar Atreya, Merce Boada, Casper de Boer, Pauline Conde, Jelena Curcic, Giovanni Frisoni, Samantha Galluzzi, Martha Therese Gjestsen, Mara Gkioka, Margarita Grammatikopoulou, Lucrezia Hausner, Chris Hinds…
    Citation: Alzheimer's Research & Therapy 2025 17:29
  30. Degeneration of the basal forebrain cholinergic system is a hallmark feature shared by Alzheimer’s disease (AD) and Lewy body disease (LBD) whereas hippocampus atrophy is more specifically related to AD. We ai...

    Authors: Julia Schumacher, Stefan Teipel and Alexander Storch
    Citation: Alzheimer's Research & Therapy 2025 17:28
  31. Alzheimer’s disease (AD) stands as the leading cause of dementia worldwide, and projections estimate over 150 million patients by 2050. AD prevalence is notably higher in women, nearly twice that of men, with ...

    Authors: Maitee Rosende-Roca, Fernando García-Gutiérrez, Yahveth Cantero-Fortiz, Montserrat Alegret, Vanesa Pytel, Pilar Cañabate, Antonio González-Pérez, Itziar de Rojas, Liliana Vargas, Juan Pablo Tartari, Ana Espinosa, Gemma Ortega, Alba Pérez-Cordón, Mariola Moreno, Sílvia Preckler, Susanna Seguer…
    Citation: Alzheimer's Research & Therapy 2025 17:27
  32. For clinical implementation of Alzheimer’s disease (AD) blood-based biomarkers (BBMs), knowledge of short-term variability, is crucial to ensure safe and correct biomarker interpretation, i.e., to capture chan...

    Authors: Frederikke Kragh Clemmensen, Mathias Holsey Gramkow, Anja Hviid Simonsen, Nicholas J. Ashton, Hanna Huber, Kaj Blennow, Henrik Zetterberg, Gunhild Waldemar, Steen Gregers Hasselbalch and Kristian Steen Frederiksen
    Citation: Alzheimer's Research & Therapy 2025 17:26
  33. Intracerebral amyloid β (Aβ) accumulation is considered the initial observable event in the pathological process of Alzheimer’s disease (AD). Efficient screening for amyloid pathology is critical for identifyi...

    Authors: Noriyuki Kimura, Kotaro Sasaki, Teruaki Masuda, Takuya Ataka, Mariko Matsumoto, Mika Kitamura, Yosuke Nakamura and Etsuro Matsubara
    Citation: Alzheimer's Research & Therapy 2025 17:25
  34. Alzheimer’s disease (AD) remains incurable, yet its long prodromal phase offers a crucial window for early intervention. Pretangle tau, a precursor to neurofibrillary tangles, plays a key role in early AD path...

    Authors: Cassandra M. Flynn, Tamunotonye Omoluabi, Alyssa M. Janes, Emma J. Rodgers, Sarah E. Torraville, Brenda L. Negandhi, Timothy E. Nobel, Shyamchand Mayengbam and Qi Yuan
    Citation: Alzheimer's Research & Therapy 2025 17:24
  35. Effective detection of cognitive impairment in the primary care setting is limited by lack of time and specialized expertise to conduct detailed objective cognitive testing and few well-validated cognitive scr...

    Authors: David P. Salmon, Anna Malkina, Melanie L. Johnson, Christina Gigliotti, Emily A. Little and Douglas Galasko
    Citation: Alzheimer's Research & Therapy 2025 17:23
  36. Many risk factors for dementia have been identified, but the timing of risk is less well understood. Here, we analyzed risk factors in a case–control study covering 10 years before an incident dementia diagnosis.

    Authors: Stefan Teipel, Manas Akmatov, Bernhard Michalowsky, Steffi Riedel-Heller, Jens Bohlken and Jakob Holstiege
    Citation: Alzheimer's Research & Therapy 2025 17:22
  37. Alzheimer's disease (AD) is a progressive neurodegenerative disorder with both genetic and environmental factors contributing to its pathogenesis. While early-onset AD has well-established genetic determinants...

    Authors: Elisa Rubino, Maria Italia, Elisa Giorgio, Silvia Boschi, Paola Dimartino, Tommaso Pippucci, Fausto Roveta, Clara Maria Cambria, Gabriella Elia, Andrea Marcinnò, Salvatore Gallone, Ekaterina Rogaeva, Flavia Antonucci, Alfredo Brusco, Fabrizio Gardoni and Innocenzo Rainero
    Citation: Alzheimer's Research & Therapy 2025 17:21
  38. The imbalance of glutamate (Glu) and gamma-aminobutyric acid (GABA) neurotransmitter system plays a crucial role in the pathogenesis of Alzheimer’s disease (AD). Riluzole is a Glu modulator originally approved...

    Authors: Yuanyu Shen, Xiaolei Zhang, Siqi Liu, Lijing Xin, Wentao Xuan, Caiyu Zhuang, Yue Chen, Beibei Chen, Xinhui Zheng, Renhua Wu and Yan Lin
    Citation: Alzheimer's Research & Therapy 2025 17:20
  39. The potential diagnostic value of plasma amyloidogenic beta residue 42/40 ratio (Aβ42/Aβ40 ratio), neurofilament light (NfL), tau phosphorylated at threonine-181 (p-tau181), and threonine-217 (p-tau217) has be...

    Authors: Swetha Ravichandran, Peter J. Snyder, Jessica Alber, Charles F. Murchison, Lauren E. Chaby, Andreas Jeromin and Edmund Arthur
    Citation: Alzheimer's Research & Therapy 2025 17:19
  40. Epidemiological and genetic studies have elucidated associations between antihypertensive medication and Alzheimer’s disease (AD), with the directionality of these associations varying upon the specific class ...

    Authors: He Zheng, Chaolei Chen and Yingqing Feng
    Citation: Alzheimer's Research & Therapy 2025 17:18
  41. Quantitative susceptibility mapping (QSM) can study the susceptibility values of brain tissue which allows for noninvasive examination of local brain iron levels in both normal and pathological conditions.

    Authors: Yian Gao, Changhu Liang, Qihao Zhang, Hangwei Zhuang, Chaofan Sui, Nan Zhang, Mengmeng Feng, Haotian Xin, Lingfei Guo and Yi Wang
    Citation: Alzheimer's Research & Therapy 2025 17:17
  42. Dementia patients commonly present multiple neuropathologies, worsening cognitive function, yet structural neuroimaging signatures of dementia have not been positioned in the context of combined pathology. In ...

    Authors: Diana Ortega-Cruz, Alberto Rabano and Bryan A. Strange
    Citation: Alzheimer's Research & Therapy 2025 17:16
  43. The safety data of lecanemab in the post-marketing period has yet to be fully investigated in the current literature. We aimed to identify and characterise the safety profile of lecanemab in the post-marketing...

    Authors: Xiaoxuan Xing, Xiaotong Zhang, Ke Wang, Zhizhou Wang, Yingnan Feng, Xiaoxi Li, Yiming Hua, Lan Zhang and Xianzhe Dong
    Citation: Alzheimer's Research & Therapy 2025 17:15
  44. Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer’s disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 rec...

    Authors: Jeffrey L. Cummings, Alireza Atri, Howard H. Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, Peter Johannsen, Teresa León and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2025 17:14
  45. Evidence indicates that cognitive function is influenced by potential environmental factors. We aimed to determine the variables influencing cognitive function.

    Authors: Yong-Li Zhao, Yi-Ning Hao, Yi-Jun Ge, Yi Zhang, Lang-Yu Huang, Yan Fu, Dan-Dan Zhang, Ya-Nan Ou, Xi-Peng Cao, Jian-Feng Feng, Wei Cheng, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2025 17:13
  46. We have previously demonstrated that the intracellular, non-GPI anchored CD59 isoforms IRIS-1 and IRIS-2 (Isoforms Rescuing Insulin Secretion 1 and 2) are necessary for insulin secretion from pancreatic β-cell...

    Authors: Ewelina Golec, Robin Olsson, Emre Can Tuysuz, Maja Karlsson, Yasmin Serjieh, Ben C. King, Malin Wennström and Anna M. Blom
    Citation: Alzheimer's Research & Therapy 2025 17:11
  47. Digital, online assessments are efficient means to detect early cognitive decline, but few studies have investigated the relationship between remotely collected subjective cognitive change and cognitive declin...

    Authors: Jae Myeong Kang, Manchumad Manjavong, Chengshi Jin, Adam Diaz, Miriam T. Ashford, Joseph Eichenbaum, Emily Thorp, Elizabeth Wragg, Kenton H. Zavitz, Francesca Cormack, Anna Aaronson, R. Scott Mackin, Rachana Tank, Bernard Landavazo, Erika Cavallone, Diana Truran…
    Citation: Alzheimer's Research & Therapy 2025 17:10
  48. Subclinical depressive symptoms increase the risk of developing Alzheimer’s disease (AD). The neurobiological mechanisms underlying this link may involve stress system dysfunction, notably related to the hippo...

    Authors: Edelweiss Touron, Robin de Flores, Laurent Coulbault, Cassandre Palix, Anne Chocat, Elizabeth Kuhn, Brigitte Landeau, Florence Mézenge, Daniel Roquet, Léa Chauveau, Sacha Haudry, Denis Vivien, Vincent de La Sayette, Natalie L. Marchant, Gaël Chételat and Géraldine Poisnel
    Citation: Alzheimer's Research & Therapy 2025 17:9